Attention Please: Pay Attention To The Case Study Sample Ess
Attention Please Pay Attention To The Case Study Sample Essa
Attention Please Pay Attention To The Case Study Sample Essa
ATTENTION!!!!!!!!! PLEASE PAY ATTENTION TO THE CASE STUDY, SAMPLE ESSAY (please follow the sample essay attached sequence because that is how the instructor wants the decision to be answered) AND CHAPTERS. GOOD INTRODUCTION. ZERO PLAGIARISM, FIVE REFERENCES Examine Case Study: Pakistani Woman with Delusional Thought Processes. You will be asked to make three decisions concerning the medication to prescribe to this client.
Be sure to consider factors that might impact the client’s pharmacokinetic and pharmacodynamic processes. At each decision point stop to complete the following:
Decision #1 Which decision did you select? Why did you select this decision? Support your response with evidence and references to the Learning Resources. What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources. Explain any difference between what you expected to achieve with Decision #1 and the results of the decision. Why were they different?
Decision #2 Why did you select this decision? Support your response with evidence and references to the Learning Resources. What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources. Explain any difference between what you expected to achieve with Decision #2 and the results of the decision. Why were they different?
Decision #3 Why did you select this decision? Support your response with evidence and references to the Learning Resources. What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources. Explain any difference between what you expected to achieve with Decision #3 and the results of the decision. Why were they different?
Paper For Above instruction
The case of a Pakistani woman exhibiting delusional thought processes presents a complex scenario that requires careful consideration of pharmacological and psychosocial factors. In psychiatric practice, selecting appropriate medication involves understanding the client’s unique needs, cultural background, pharmacokinetic and pharmacodynamic properties, and potential medication interactions. This paper outlines three crucial decision points in prescribing medication, supported by current evidence and best practices.
Decision #1: Initiation of Antipsychotic Treatment with Risperidone
The first decision involves starting treatment with a second-generation antipsychotic, risperidone. Risperidone is commonly used for delusional disorders due to its efficacy in reducing positive symptoms such as hallucinations and delusions (Miyamoto et al., 2012). I selected risperidone because it has a relatively favorable side effect profile and is effective in diverse populations, including those from South Asian backgrounds. Pharmacokinetically, risperidone undergoes extensive hepatic metabolism via CYP2D6 enzymes—factors that can be influenced by genetic variations prevalent in the Pakistani population (Aslam et al., 2018). Its pharmacodynamic action includes dopamine D2 receptor antagonism, which helps alleviate psychotic symptoms.
The aim of initiating risperidone was to reduce the patient’s delusional thoughts effectively, improve insight, and decrease distress. I expected improvement in psychotic symptoms within 1-2 weeks, based on typical clinical response times. However, if side effects like extrapyramidal symptoms or weight gain occurred, they could diminish adherence or necessitate dosage adjustments (Correll, 2017).
Decision #2: Monitoring and Adjusting Dosage Based on Pharmacokinetic Factors
The second decision involves closely monitoring the patient for side effects and response, with consideration for genetic or physiological factors affecting pharmacokinetics. For example, hepatic function and CYP2D6 enzyme activity can alter risperidone metabolism, impacting plasma drug levels (Kwon et al., 2016). Given the prevalence of CYP2D6 polymorphisms in South Asian populations, I opted for starting at a lower dose and titrating upward cautiously. This approach aims to optimize therapeutic effects while minimizing adverse reactions.
The goal here was to achieve an effective dose that manages symptoms without intolerable side effects. I anticipated that careful titration would result in symptom control within 4-6 weeks. Unexpectedly, some patients may display reduced response or heightened side effects due to metabolic variations, which could require further dose adjustments or switching medications (Baldassarre et al., 2018). This highlights the importance of individualized treatment plans.
Decision #3: Incorporating Psychosocial Interventions and Cultural Competence
The third decision emphasizes integrating psychosocial support and considering cultural factors influencing treatment adherence and insight. Cultural beliefs about mental illness, stigma, and religious practices can affect the patient’s engagement with treatment (Eack et al., 2013). I selected culturally sensitive psychoeducation, involving family members if appropriate, to improve understanding and support. Additionally, incorporating cognitive-behavioral therapy (CBT) tailored to cultural norms can enhance therapeutic outcomes.
The aim was to sustain medication adherence, reduce stigma, and promote recovery. I expected that combining pharmacotherapy with psychosocial interventions would lead to better long-term outcomes. However, cultural barriers or misconceptions could limit engagement or acceptance, potentially delaying recovery. Recognizing these differences underscores the need for culturally competent care, which influences treatment success.
Conclusion
Treating a Pakistani woman with delusional thought processes requires a multifaceted approach that considers pharmacokinetic and pharmacodynamic factors, cultural background, and psychosocial support. Initiating risperidone with careful monitoring, adjusting doses based on pharmacogenetic considerations, and integrating culturally appropriate interventions are essential. These decisions aim to improve symptoms, promote adherence, and support recovery, reflecting evidence-based practices tailored to individual needs.
References
- Aslam, N., Khan, S., & Zahid, S. (2018). Pharmacogenetic variations in CYP2D6 and their clinical implications in South Asian populations. Journal of Clinical Pharmacology, 58(9), 1134-1142.
- Baldassarre, A., Caccia, S., & Sartori, L. (2018). Pharmacokinetic variability in antipsychotic treatment: Impact of CYP2D6 polymorphisms. Psychiatria Danubina, 30(3), 287-292.
- Correll, C. U. (2017). Antipsychotic side effects. CNS Spectrums, 22(4), 549-555.
- Eack, S. M., et al. (2013). Cultural considerations in psychosis management. Psychiatric Services, 64(8), 722-728.
- Kwon, J. S., et al. (2016). Pharmacogenetics of antipsychotic treatment. Therapeutic Advances in Psychopharmacology, 6(4), 389-404.
- Miyamoto, S., et al. (2012). Pharmacological treatment of schizophrenia: An update. Dialogues in Clinical Neuroscience, 14(4), 377-389.